Indeed, the combination of SRS with IT prolongs survival in patients with melanoma BMs [109–111], and several clinical trials, including a pilot studying evaluating CTLA-4 and PD-L1 inhibition with RT (NCT02563925), are ongoing in BCBM patients (Table 1). The gene discussed is CD274; the disease is melanoma.